




# Allergic Rhinitis

## Clinical Guideline

### BASIC CARE PLAN



GRADE: Grading of recommendations assessment, development and evaluation; ARIA: Allergic rhinitis and its impact on asthma; AIT: Allergen immunotherapy

### RECOMMENDATION

1

For severe allergic rhinitis (SAR):  
Intranasal corticosteroids (INCS) + Oral  
antihistamine (OAH) or INCS alone

2

For persistent allergic rhinitis:  
INCS alone or  
INCS + Intranasal antihistamine (INAH)

3

For SAR: INCS + INAH or INCS alone



# PHARMACOTHERAPY



OAH or INAH are less efficient than INCS in controlling all rhinitis symptoms. They are beneficial in many people with mild/moderate illness, and several people prefer oral drugs over intra-nasal treatments.

The benefit of OAH or INAH is not yet clear.

INCS is the first-line of choice for SAR. However, the effect can be seen only after few days.

The combination of an OAH and INCS does not result in greater efficacy than the INCS monotherapy.

OAH or INCS is advised only if monotherapy with INCS is found inadequate, in SAR cases, or for patients requiring immediate symptom relief.

The combination of intranasal fluticasone propionate and azelastine in a single device is more beneficial.

Nasal vasoconstrictors, as well as first-generation OAH are sedatives and must be avoided for long durations.

The use of intramuscular depot corticosteroids is contraindicated.

*GRADE: Grading of recommendations assessment, development and evaluation; ARIA: Allergic rhinitis and its impact on asthma; AIT: Allergen immunotherapy; SAR: Severe allergic rhinitis; INCS: Intranasal corticosteroids; OAH: Oral Antihistamine; INAH: Intranasal antihistamine.*

*Gotua M, Gamkrelidze A, Rukhadze M, et al. 2020 ARIA CARE PATHWAYS FOR ALLERGIC RHINITIS - GEORGIA. Georgian Med News. 2019;(297):108-117*

For the use of a Registered Medical Practitioner, Hospital or Laboratory only.

All content including: text, images, audio, or other formats were created for medical educational purposes only. Offerings for continuing education are clearly identified and the appropriate target audience is identified. This communication is restricted for the use of HCPs and must not be shared in public domain. The opinions expressed in this video are solely the views of the speaker. The presentation may contain off label usage of drug(s) aimed at educational purpose only. Dr. Reddy's Laboratories Ltd including but not limited its Affiliates strictly does not recommend any off label usage of its marketing products. Prior to treatment kindly refer to the latest prescribing information approved by the local authorities. No part of this content may be used, reproduced, transmitted or stored in any form without the written permission of Dr. Reddy's.

From the makers of  
**Cetzine**<sup>®</sup>